Chargement en cours...
Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
Dulaglutide is a once‐weekly glucagon‐like peptide‐1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chro...
Enregistré dans:
| Publié dans: | Diabetes Obes Metab |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Blackwell Publishing Ltd
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347883/ https://ncbi.nlm.nih.gov/pubmed/27766728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12816 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|